FrancophonIA/ELRC3.0 huggingface dataset:
English: Each film-coated tablet contains 24.3 mg sacubitril and 25.7 mg valsartan (as sacubitril valsartan sodium salt complex).
Croatian: Svaka filmom obložena tableta sadrži 24,3 mg sakubitrila i 25,7 mg valsartana (u obliku sakubitril valsartan kompleksa natrijeve soli).
English: • low level of potassium in the blood (shown in a blood test)
Croatian: • niska razina kalija u krvi (vidljivo iz krvne pretrage)
English: o Each 24 mg/26 mg film-coated tablet contains 24.3 mg sacubitril and 25.7 mg valsartan (as sacubitril valsartan sodium salt complex).
Croatian: o Svaka 24 mg/26 mg filmom obložena tableta sadrži 24,3 mg sakubitrila i 25,7 mg valsartana (u obliku sakubitril valsartan kompleksa natrijeve soli).
English: Patients with renal artery stenosis
Croatian: Bolesnici sa stenozom bubrežne arterije
English: If you stop taking Neparvis, wait 36 hours after taking your last dose of Neparvis before starting an ACE inhibitor.
Croatian: Ako prestanete uzimate Neparvis, pričekajte 36 sati nakon uzimanja posljednje doze Neparvisa prije nego počnete uzimati ACE inhibitor (vidjeti „Uzimanje drugih lijekova“).
English: o Each 49 mg/51 mg film-coated tablet contains 48.6 mg sacubitril and 51.4 mg valsartan (as sacubitril valsartan sodium salt complex).
Croatian: o Svaka 49 mg/51 mg filmom obložena tableta sadrži 48,6 mg sakubitrila i 51,4 mg valsartana (u obliku sakubitril valsartan kompleksa natrijeve soli).
English: Each 24 mg/26 mg tablet contains 24.3 mg sacubitril and 25.7 mg valsartan (as sacubitril valsartan sodium salt complex).
Croatian: Svaka tableta od 24 mg/26 mg sadrži 24,3 mg sakubitrila i 25,7 mg valsartana (u obliku sakubitril valsartan kompleksa natrijeve soli).
English: Vascular disorders
Croatian: Magnezijev stearat
English: Talc
Croatian: Talk
English: • tiredness
Croatian: • omaglica
English: Each 49 mg/51 mg tablet contains 48.6 mg sacubitril and 51.4 mg valsartan (as sacubitril valsartan sodium salt complex).
Croatian: Svaka tableta od 49 mg/51 mg sadrži 48,6 mg sakubitrila i 51,4 mg valsartana (u obliku sakubitril valsartan kompleksa natrijeve soli).
English: o Each 97 mg/103 mg film-coated tablet contains 97.2 mg sacubitril and 102.8 mg valsartan (as sacubitril valsartan sodium salt complex).
Croatian: o Svaka 97 mg/103 mg filmom obložena tableta sadrži 97,2 mg sakubitrila i 102,8 mg valsartana (u obliku sakubitril valsartan kompleksa natrijeve soli).
English: • fainting
Croatian: • nesvjestica
English: Each 97 mg/103 mg tablet contains 97.2 mg sacubitril and 102.8 mg valsartan (as sacubitril valsartan sodium salt complex).
Croatian: Svaka tableta od 97 mg/103 mg sadrži 97,2 mg sakubitrila i 102,8 mg valsartana (u obliku sakubitril valsartan kompleksa natrijevih soli).
English: Cough
Croatian: Kalij
English: Colloidal anhydrous silica
Croatian: Silicijev dioksid, koloidni, bezvodni
English: Nausea
Croatian: Vrtoglavica
English: Dizziness postural
Croatian: Prijavljivanje nuspojava
English: Preferred term
Croatian: Krajnji rok
English: Anaemia
Croatian: Astenija
English: Irbesartan 300
Croatian: 6.3 Rok valjanosti
English: ITP in adults
Croatian: ITP u odraslih
English: ITP in children
Croatian: ITP u djece
English: Further information on Revolade can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Revolade.
Croatian: Više informacija o lijeku Revolade nalazi se na internetskim stranicama Agencije:ema.europa.eu/medicines/human/EPAR/Revolade.
English: Revolade is a medicine that is used for the treatment of:
Croatian: Revolade je lijek koji se primjenjuje za liječenje:
English: Revolade received a marketing authorisation valid throughout the EU on 11 March 2010.
Croatian: Lijek Revolade dobio je odobrenje za stavljanje u promet koje je na snazi u EU-u od 11. ožujka 2010.
English: This overview was last updated in 03-2019.
Croatian: Pregled informacija posljednji je put ažuriran u 3. 2019.
English: What measures are being taken to ensure the safe and effective use of Revolade?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Revolade?
English: Other information about Revolade
Croatian: Ostale informacije o lijeku Revolade
English: What is Revolade and what is it used for?
Croatian: Što je Revolade i za što se primjenjuje?
English: Severe aplastic anaemia
Croatian: Teška aplastična anemija
English: The medicine can only be obtained with a prescription and treatment should be started and supervised by a doctor who has experience in treating blood diseases or chronic hepatitis C and its complications.
Croatian: Lijek se izdaje samo na liječnički recept, a liječenje treba započeti i nadzirati liječnik s iskustvom u liječenju krvnih bolesti ili kroničnog hepatitisa C i njegovih komplikacija.
English: For ITP and aplastic anaemia, a lower starting dose should be used in patients of Asian descent (such as Chinese, Japanese, Korean or Taiwanese people).
Croatian: Za ITP i aplastičnu anemiju može biti potrebna niža početna doza u bolesnika azijskog podrijetla (poput Kineza, Japanaca, Korejaca i Tajvanaca).
English: Preliminary data from a supportive study are consistent with the result of the main study, with 46% of patients responding to treatment after 12 weeks.
Croatian: Preliminarni podatci iz popratnog ispitivanja u skladu su s rezultatima glavnog ispitivanja, pri čemu je 46 % bolesnika reagiralo na liječenje nakon 12 tjedana.
English: Why is Revolade authorised in the EU?
Croatian: Zašto je Revolade odobren u EU-u?
English: Revolade is available as tablets (12.5, 25, 50 and 75 mg) and as a powder (25 mg) to prepare a suspension (a liquid) to be taken by mouth.
Croatian: Revolade je dostupan u obliku tableta (od 12,5; 25; 50 i 75 mg) i praška (25 mg) za pripremu suspenzije (tekućine) koji se uzimaju na usta.
English: • thrombocytopenia in adults with chronic (long-term) hepatitis C, a liver disease caused by the hepatitis C virus.
Croatian: • trombocitopenije u odraslih s kroničnim (dugotrajnim) hepatitisom C, bolešću koju uzrokuje virus hepatitisa C.
English: Side effects reported with Revolade are carefully evaluated and any necessary action taken to protect patients.
Croatian: Nuspojave prijavljene za lijek Revolade pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
English: For the treatment of thrombocytopenia associated with hepatitis C, two main studies involving a total of 1,441 adults were carried out.
Croatian: Za liječenje trombocitopenije povezane s hepatitisom C provedena su dva glavna ispitivanja kojima je bila obuhvaćena ukupno 1 441 odrasla osoba.
English: For the treatment of severe aplastic anaemia, Revolade was studied in 43 patients and it was not compared with any other medicine.
Croatian: Za liječenje teške aplastične anemije Revolade je ispitivan u 43 bolesnika te nije uspoređivan s drugim lijekovima.
English: As for all medicines, data on the use of Revolade are continuously monitored.
Croatian: Kao i za sve lijekove, podatci o primjeni lijeka Revolade kontinuirano se prate.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Revolade have been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Revolade nalaze se u sažetku opisa svojstava i u uputi o lijeku.
English: In both studies, the main measure of effectiveness was the number of patients whose blood tests did not show any sign of hepatitis C virus 6 months after the end of treatment.
Croatian: U oba ispitivanja glavno mjerilo djelotvornosti bio je broj bolesnika čiji rezultati krvnih pretraga 6 mjeseci nakon završetka liječenja nisu pokazivali znakove virusa hepatitisa C.
English: Revolade is used in patients from 1 year of age who have had the disease for at least 6 months and for whom treatment with medicines such as corticosteroids or immunoglobulins has not worked;
Croatian: Revolade se primjenjuje u bolesnika u dobi od godinu dana i starijih koji boluju od ove bolesti barem šest mjeseci, kod kojih terapija lijekovima poput kortikosteroida ili imunoglobulina nije djelovala;
English: The European Medicines Agency decided that Revolade's benefits are greater than its risks and recommended that it be authorised for use in the EU.
Croatian: Europska agencija za lijekove zaključila je da koristi od lijeka Revolade nadmašuju s njim povezane rizike te da lijek može biti odobren za primjenu u Europskoj uniji.
English: For the treatment of ITP in adults, Revolade was compared with placebo (a dummy treatment) in two main studies involving a total of 311 patients who had previously been treated, but the treatments had not worked or the disease had come back.
Croatian: Za liječenje ITP-a u odraslih, Revolade je uspoređen s placebom (prividnim liječenjem) u dvama glavnim ispitivanjima u kojima je sudjelovalo ukupno 311 bolesnika koji su prethodno bili liječeni, ali liječenje nije djelovalo ili se bolest vratila.
English: What are the risks associated with Revolade?
Croatian: Koji su rizici povezani s lijekom Revolade?
English: In children with ITP, Revolade was more effective than placebo in one main study involving 92 children between 1 and 17 years of age who had previously been treated for ITP.
Croatian: U djece s ITP-om Revolade je bio djelotvorniji od placeba u jednom glavnom ispitivanju koje je obuhvatilo 92 djece u dobi od 1 do 17 godina koja su prethodno bila liječena zbog ITP-a.
English: Revolade is used when the thrombocytopenia is too severe to allow interferonbased therapy (type of treatment for hepatitis C );
Croatian: Revolade se primjenjuje kad je stadij trombocitopenije preozbiljan za liječenje na bazi interferona (vrste terapije za hepatitis C);
English: An overview of Revolade and why it is authorised in the EU
Croatian: Pregled informacija o lijeku Revolade i zašto je odobren u EU-u
English: Thrombocytopenia associated with hepatitis C
Croatian: Trombocitopenija povezana s hepatitisom C
English: For more information about using Revolade, see the package leaflet or contact your doctor or pharmacist.
Croatian: Više informacija o primjeni lijeka Revolade pročitajte u uputi o lijeku, odnosno obratite se liječniku ili ljekarniku.
English: Revolade is used in adult patients whose disease is not controlled by immunosuppressive therapy (medicines that lower the body's immune defences) and cannot receive haematopoietic stem cell transplantation (where the patient's bone marrow is replaced by stem cells from a donor to form new bone marrow).
Croatian: Revolade se primjenjuje u odraslih čija se bolest ne kontrolira imunosupresivnom terapijom (lijekovima koji smanjuju imunosnu obranu organizma) i ne mogu primiti presađivanje krvotvornih matičnih stanica (kada se koštana srž bolesnika mijenja matičnim stanicama donatora kako bi se formirala nova koštana srž).
English: An extension of the study found that Revolade was effective at maintaining adequate levels of platelets in the long term.
Croatian: U proširenom ispitivanju utvrđeno je da je lijek Revolade bio djelotvorniji u dugoročnom održavanju odgovarajućih razina trombocita.
English: The most important serious side effects are febrile neutropenia (low white blood cell counts with fever) and infection.
Croatian: Najvažnije ozbiljne nuspojave uključuju febrilnu neutropeniju (nizak broj bijelih krvnih stanica praćen vrućicom) i infekciju.
English: In this study, 40% of patients (17 out of 43) responded to treatment after 12 weeks, and in 65% of them (11 out of 17) the platelet count either increased by at least 20,000 per microliter or it was stable without a need for blood transfusions.
Croatian: U tom ispitivanju, 40 % bolesnika (17 od 43) reagiralo je na liječenje nakon 12 tjedana, a u 65 % bolesnika koji su reagirali na liječenje (11 od 17) broj trombocita povećao se najmanje za 20 000 po mikrolitri ili je bio stabilan, bez potrebe za transfuzijom krvi.
English: Revolade contains the active substance eltrombopag.
Croatian: Revolade sadrži djelatnu tvar eltrombopag.
English: In these two studies, a higher proportion of patients who took Revolade tested negative for hepatitis C, compared with those who took placebo (23% versus 14% in the first study, and 19% versus 13% in the second study).
Croatian: U tim dvama ispitivanjima, veći udio bolesnika koji su uzimali Revolade bio je negativan na hepatitis C, u usporedbi s bolesnicima koji su uzimali placebo (23 % u odnosu na 14 % u prvom ispitivanju, te 19 % u odnosu na 13 % u drugom ispitivanju).
English: Revolade was more effective than placebo: in the first study, 59% of the patients who took Revolade (43 out of 73) achieved a platelet count of at least 50,000 per microlitre (which is considered adequate to prevent bleeding complications) after 6 weeks of treatment, compared with 16% of those who took placebo (6 out of 37).
Croatian: Revolade je bio djelotvorniji od placeba: u prvom ispitivanju 59 % bolesnika koji su uzimali Revolade (43 od 73) doseglo je razinu trombocita od najmanje 50 000 po mikrolitri (što se smatra odgovarajućom razinom za sprječavanje komplikacija krvarenja) nakon šest tjedana liječenja, u usporedbi sa 16 % bolesnika koji su primali placebo (6 od 37).
English: The most common side effects with Revolade in adults with ITP (which may affect more than 1 in 10 people) are nausea (feeling sick), diarrhoea and abnormal blood levels of certain liver enzymes.
Croatian: Najčešće nuspojave lijeka Revolade u odraslih s ITP-om (koje se mogu javiti u više od 1 od 10 osoba) su mučnina (slabost), proljev i abnormalne razine određenih jetrenih enzima u krvi.
English: This occurred in around 40% of those taking Revolade (25 out of 63) compared with around 3% (1 out of 29) of those who took placebo.
Croatian: To se povećanje dogodilo u približno 40 % bolesnika koji su primali Revolade (25 od 63) u usporedbi s približno 3 % (1 od 29) bolesnika koji su primali placebo.
English: The most important serious side effects are liver problems and thromboembolic complications (problems with clots in blood vessels).
Croatian: Najvažnije ozbiljne nuspojave su problemi s jetrom i tromboembolične komplikacije (problemi s ugrušcima u krvnim žilama).
English: These compared Revolade with placebo for allowing the starting and maintenance of antiviral treatment in patients with hepatitis C whose platelet count was initially too low to allow starting such treatment (less than 75,000 per microlitre).
Croatian: U tim je ispitivanjima Revolade uspoređen s placebom u svrhu započinjanja i održavanja antivirusnog liječenja bolesnika s hepatitisom C čiji je broj trombocita na početku liječenja bio prenizak da bi se takvo liječenje moglo započeti (manje od 75 000 po mikrolitri).
English: Important serious side effects are liver problems and thromboembolic complications.
Croatian: Važne ozbiljne nuspojave uključuju probleme s jetrom i tromboembolijske komplikacije.
English: The dose depends on the patient's age and the disease for which Revolade is being used; it is adjusted as needed to maintain the appropriate platelet level.
Croatian: Doza ovisi o dobi bolesnika i bolesti koja se liječi lijekom Revolade te se prilagođava prema potrebi kako bi se održala odgovarajuća razina trombocita.
English: • primary immune thrombocytopenia (ITP), a disease in which the patient's immune system destroys platelets (components in the blood that help it to clot).
Croatian: • primarne imune trombocitopenije (ITP), bolesti u kojoj imunosni sustav bolesnika uništava trombocite (krvne stanice koje pomažu u zgrušavanju krvi).
English: The main measure of effectiveness was the number of patients who responded to Revolade (whose platelet, red or white blood cell count remained above pre-set levels) after 12 or 16 weeks of treatment.
Croatian: Glavno mjerilo djelotvornosti bio je broj bolesnika koji su reagirali na Revolade (odnosno kod kojih je broj trombocita, eritrocita ili leukocita ostao iznad prethodno utvrđenih razina) nakon 12 ili 16 tjedana liječenja.
English: Patients with ITP have low platelet counts in the blood (thrombocytopenia) and are at risk of bleeding.
Croatian: Bolesnici s ITP-om imaju mali broj trombocita (trombocitopeniju) i izloženi su riziku od krvarenja.
English: In the body, a hormone called ‘thrombopoietin' stimulates the production of platelets by attaching to certain receptors (targets) in the bone marrow.
Croatian: Hormon „trombopoetin” potiče stvaranje trombocita u tijelu vezivanjem na određene receptore (ciljna mjesta) u koštanoj srži.
English: • acquired severe aplastic anaemia (a disease in which the bone marrow does not make enough blood cells or platelets).
Croatian: • stečeneteške aplastične anemije (bolesti kod koje koštana srž ne proizvodi dovoljno krvnih stanica ili trombocita).
English: How does Revolade work?
Croatian: Kako djeluje Revolade?
English: In children with ITP, the most common side effects include nose and throat infection, cough, fever, pain in the belly or in the mouth and throat, toothache and runny nose.
Croatian: U djece s ITP-om najčešće nuspojave uključuju infekcije nosa i grla, kašalj, vrućicu, bolove u trbuhu ili u ustima i grlu, zubobolju i curenje iz nosa.
English: The active substance in Revolade, eltrombopag, also attaches to and stimulates the thrombopoietin receptors.
Croatian: Djelatna tvar lijeka Revolade, eltrombopag, također se veže na receptore trombopoetina te ih stimulira.
English: In patients with thrombocytopenia and advanced chronic hepatitis C who are treated with interferon and Revolade, the most common side effects include headache, anaemia (low red blood cell counts), decreased appetite, cough, nausea, diarrhoea, high levels of bilirubin in the blood, hair loss, itching, muscle pain, fever, tiredness, flu-like illness, weakness, chills and swelling (because of build-up of water in the body).
Croatian: U bolesnika s trombocitopenijom i uznapredovalim kroničnim hepatitisom C koji se liječe lijekovima interferon i Revolade, najčešće nuspojave su glavobolja, anemija (niske razine crvenih krvnih zrnaca), smanjeni apetit, kašalj, mučnina, proljev, visoke razine bilirubina u krvi, gubitak kose, svrbež, bol u mišićima, vrućica, umor, simptomi slični gripi, slabost, zimica i oticanje (zbog nakupljanja vode u organizmu).
English: In the second study, patients taking Revolade were around 8 times more likely than those taking placebo to reach the target platelet count of between 50,000 and 400,000 per microlitre during the 6 months of treatment.
Croatian: U drugom ispitivanju, bolesnici koji su uzimali Revolade imali su osam puta veću vjerojatnost za dosezanje ciljane razine broja trombocita od 50 000 do 400 000 po mikrolitri tijekom šest mjeseci liječenja u odnosu na bolesnike koji su primali placebo.
English: This study lasted 13 weeks and looked at the proportion of patients whose platelet count had increased to at least 50,000 per microlitre for at least 6 out of 8 weeks, between week 5 to 12 of the study in the absence of rescue medication.
Croatian: To je ispitivanje trajalo 13 tjedana te se u njemu promatrao udio bolesnika čiji se broj trombocita povećao na najmanje 50 000 po mikrolitri tijekom barem 6 od 8 tjedana između 5. i 12. tjedna ispitivanja bez lijeka za brzo djelovanje.
English: What benefits of Revolade have been shown in studies?
Croatian: Koje su koristi od lijeka Revolade utvrđene u ispitivanjima?
English: In adults with severe aplastic anaemia the most common side effects include headache, dizziness, cough, pain in the belly or in the mouth and throat, nausea, diarrhoea, joint pain, pain in limbs, tiredness, fever and abnormal blood levels of certain liver enzymes.
Croatian: U odraslih s teškom aplastičnom anemijom najčešće nuspojave uključuju glavobolju, vrtoglavicu, kašalj, bolove u trbuhu ili u ustima i grlu, mučninu, proljev, bol u zglobovima i udovima, umor, vrućicu i abnormalne razine određenih jetrenih enzima u krvi.
English: For the full list of restrictions and side effects of Revolade, see the package leaflet.
Croatian: Potpuni popis ograničenja i nuspojava pri primjeni lijeka Revolade potražite u uputi o lijeku.
English: Patients should not take medicines such as antacids or dairy products and mineral supplements in the 4 hours before and in the 2 hours after taking Revolade.
Croatian: Četiri sata prije ili dva sata nakon uzimanja lijeka Revolade bolesnici ne smiju uzimati lijekove poput antacida ili mliječne proizvode kao ni nadomjestke minerala.
English: This increases the production of platelets, improving platelet counts.
Croatian: Na taj se način povećava proizvodnja trombocita te njihova razina.
English: How is Revolade used?
Croatian: Kako se lijek Revolade primjenjuje?
English: if you are more than 3 months pregnant.
Croatian: ako ste trudni više od 3 mjeseca.
English: Check with your doctor if you are not sure.
Croatian: Provjerite s liječnikom ako niste sigurni.
English: In some cases you may have to stop taking one of the medicines.
Croatian: U nekim slučajevima ćete možda morati prekinuti uzimati jedan od lijekova.
English: Then take your next dose at its usual time.
Croatian: Zatim uzmite sljedeću dozu u uobičajeno vrijeme.
English: Within 2 years after Commission Decision.
Croatian: U roku od dvije godine od Odluke Komisije.
English: This applies especially to the medicines listed below:
Croatian: To se posebno odnosi na lijekove koji su niže navedeni:
English: If you forget to take this medicine, take it as soon as you remember.
Croatian: Ako zaboravite uzeti ovaj lijek, uzmite ga čim se sjetite.
English: Not to be sold separately.
Croatian: Ne smije se prodavati zasebno.
English: Distribution: Volume of distribution is approximately 21 l/kg.
Croatian: Distribucija: Volumen distribucije je otprilike 21 l/kg.
English: So, if you are not sure how this medicine will affect you, do not drive, use machinery, or do other activities that you need to concentrate on.
Croatian: Stoga, ako niste sigurni kako će ovaj lijek djelovati na Vas, nemojte voziti, upravljati strojevima ili se baviti drugim aktivnostima koje zahtijevaju koncentraciju.
English: Your doctor may need to change your dose and/or to take other precautions.
Croatian: Liječnik će Vam možda morati promijeniti dozu i/ili poduzeti druge mjere opreza.
English: Depending on how you respond to the treatment, your doctor may suggest a higher or lower dose.
Croatian: Ovisno o tome kako reagirate na liječenje, liječnik Vam može predložiti višu ili nižu dozu.
English: • Shock (including cardiogenic shock).
Croatian: • Šok (uključujući kardiogeni šok).
English: The half-life of valsartan is 6 hours.
Croatian: Poluvijek valsartana je 6 sati.
English: 10.3 NA NA 9.0 9.5
Croatian: 10,3 ND ND 9,0 9,5
English: It is recommended to take Dafiro with some water.
Croatian: Preporučuje se uzeti Dafiro s nešto vode.
English: (It is also better to avoid Dafiro in early pregnancy, see Pregnancy section).
Croatian: (Također je bolje izbjegavati Dafiro u ranoj trudnoći, vidjeti dio Trudnoća).
English: Do not exceed the prescribed dose.
Croatian: Nemojte prekoračiti propisanu dozu.
English: Dafiro with food and drink
Croatian: Dafiro s hranom i pićem
English: Absolute bioavailability has been calculated as between 64% and 80%.
Croatian: Apsolutna bioraspoloživost je izračunata između 64% i 80%.
English: See also information under the heading “Do not take Dafiro”.
Croatian: Vidjeti također informacije pod naslovom „Nemojte uzimati Dafiro“.
English: It is preferable to take your medicine at the same time each day.
Croatian: Savjetuje se uzimanje lijeka svakoga dana po mogućnosti u isto vrijeme.
English: - Swelling of the tongue and throat which causes great difficulty breathing.
Croatian: - Oticanje jezika i grla koje uzrokuje velike teškoće pri disanju.
English: Dantrolene (infusion)
Croatian: Dantrolen (infuzija)
English: Not all pack sizes may be available in your country.
Croatian: U Vašoj zemlji ne moraju biti dostupne sve veličine pakiranja.
English: This can affect how well you can concentrate.
Croatian: To može utjecati na Vašu sposobnost koncentracije.
English: Elderly (age 65 years or over)
Croatian: Starije osobe (65 godina ili više)
English: % of patients who experienced peripheral oedema
Croatian: % bolesnika koji su imali periferne edeme